Nanobiotix S.A. Stock Price, News & Analysis
Company Description
Nanobiotix S.A. (NBTX) stock represents ownership in Nanobiotix, a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches for serious diseases, particularly cancer. The company is incorporated in France and is listed on both Euronext Paris and the Nasdaq Global Select Market, giving it a presence in European and U.S. equity markets.
Nanobiotix was incorporated in 2003 and is headquartered in Paris, France. According to company disclosures, its shares have traded on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. Nanobiotix reports that it has subsidiaries in Cambridge, Massachusetts in the United States among other locations, reflecting an operational footprint that spans Europe and North America.
Business focus and technology platforms
Nanobiotix describes itself as a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches intended to improve treatment outcomes for millions of patients. The company’s philosophy is rooted in pushing beyond existing scientific boundaries to expand possibilities for human life. Its work centers on nanotechnology platforms applied to medicine.
Nanobiotix states that it owns more than 25 patent families or umbrella patents associated with three nanotechnology platforms. These platforms have applications in three main areas: (1) oncology, (2) bioavailability and biodistribution, and (3) disorders of the central nervous system. This intellectual property base underpins both its oncology product candidate JNJ-1900 (also referred to as NBTXR3) and its Curadigm Nanoprimer platform.
JNJ-1900 (NBTXR3) oncology program
Nanobiotix’s principal oncology product candidate is JNJ-1900 (NBTXR3). Company materials describe JNJ-1900 (NBTXR3) as a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles. It is administered via a one-time intratumoral injection and is activated by radiotherapy. Nanobiotix reports that proof-of-concept for this product candidate was achieved in soft tissue sarcomas through a randomized Phase 2/3 study completed in 2018.
According to the company, the mechanism of action of JNJ-1900 (NBTXR3) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy. This is described as subsequently triggering an adaptive immune response and long-term anti-cancer memory. Nanobiotix states that, given this physical mechanism of action, JNJ-1900 (NBTXR3) could be scalable across solid tumors that can be treated with radiotherapy and across therapeutic combinations, particularly with immune checkpoint inhibitors.
JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or in combination with other therapies. The program is led by NANORAY-312, which Nanobiotix describes as a global, randomized Phase 3 study in patients with locally advanced head and neck squamous cell cancers who are not eligible for cisplatin. The company reports that in February 2020 the United States Food and Drug Administration granted Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for this patient population.
Nanobiotix has also entered into collaborations to support the development of JNJ-1900 (NBTXR3). In 2019, the company entered into a broad clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. The company has reported the transfer of sponsorship and operational control of the Phase 3 NANORAY-312 study in most regions to Johnson & Johnson.
Curadigm Nanoprimer platform
Beyond oncology, Nanobiotix is advancing the Curadigm Nanoprimer platform, which it describes as an early-stage nanotherapeutic platform designed to influence the design and development of intravenously administered therapeutics. The Curadigm Nanoprimer is built from precisely engineered lipid-based nanoparticles and is intended to address challenges in extrahepatic delivery of innovative agents administered intravenously, such as RNA-based vaccines, peptide-based vaccines, and oncolytic viruses.
According to company communications, the Curadigm Nanoprimer is designed to transiently occupy liver pathways responsible for therapeutic clearance. By doing so, it is intended to allow a greater fraction of subsequently administered therapeutic agents to reach target tissues, with the potential to increase drug bioavailability or reduce unintended off-target effects in the liver, including hepatic toxicity. Nanobiotix has reported filing new patent applications to expand the intellectual property foundation of the Curadigm platform and has indicated that it is pursuing both internal proprietary product development and external collaborations based on this platform.
Intellectual property and collaboration strategy
Nanobiotix emphasizes its ownership of more than 25 patent families or umbrella patents across its three nanotechnology platforms. The company has indicated that these patents cover applications in oncology, bioavailability and biodistribution, and central nervous system disorders. It has also highlighted multiple new patent applications related to the Curadigm Nanoprimer platform aimed at supporting future product candidates and collaboration opportunities.
In oncology, Nanobiotix’s collaboration strategy includes its clinical research collaboration with MD Anderson and its license agreement with Janssen Pharmaceutica NV for JNJ-1900 (NBTXR3). The company has also reported that its Curadigm Nanoprimer platform is the subject of numerous material transfer agreements with biotechnology and pharmaceutical partners who are conducting exploratory evaluations of Nanoprimer combinations.
Capital markets profile
Nanobiotix is listed on Euronext Paris and the Nasdaq Global Select Market under the symbol NBTX. The company has reported that its shares are included in the CAC Mid 60 and SBF 120 indices on Euronext Paris following an index review by the Euronext Scientific Council. It also periodically publishes information on the number of shares outstanding and total voting rights in accordance with French regulatory requirements, reflecting its status as a French public company.
Nanobiotix has disclosed that it entered into a royalty-based financing agreement with HealthCare Royalty (HCRx), under which HCRx will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3) payable to Nanobiotix under its license agreement with Janssen. The company has described this transaction as non-dilutive capital intended to support development of JNJ-1900 (NBTXR3) and its next-wave nanotherapeutic platforms.
Corporate philosophy
In its public communications, Nanobiotix states that it is supported by people committed to making a difference for humanity and that its philosophy is based on pushing past the boundaries of what is known to expand possibilities for human life. This framing aligns with its focus on physics-based therapeutic approaches and nanotechnology platforms intended to address major diseases.
Frequently asked questions about Nanobiotix (NBTX)
- What does Nanobiotix S.A. do?
Nanobiotix is a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches. It develops nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system. - Where is Nanobiotix headquartered?
Nanobiotix reports that it is headquartered in Paris, France. The company also states that it has subsidiaries in Cambridge, Massachusetts in the United States among other locations. - On which exchanges is NBTX stock listed?
According to company disclosures, Nanobiotix is listed on Euronext Paris and on the Nasdaq Global Select Market in New York City, where it trades under the symbol NBTX. - What is JNJ-1900 (NBTXR3)?
JNJ-1900 (also referred to as NBTXR3) is Nanobiotix’s oncology product candidate composed of functionalized hafnium oxide nanoparticles. It is administered via a one-time intratumoral injection and activated by radiotherapy, with a mechanism of action designed to induce tumor cell death and trigger an adaptive immune response. - What stage of development is JNJ-1900 (NBTXR3) in?
Nanobiotix describes itself as a late-stage clinical company and reports that JNJ-1900 (NBTXR3) is being evaluated in a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers (NANORAY-312), along with multiple Phase 1 and Phase 2 studies across tumor types and therapeutic combinations. - What is the Curadigm Nanoprimer platform?
The Curadigm Nanoprimer platform is an early-stage nanotherapeutic platform developed by Nanobiotix. It is designed for use in combination with intravenously administered therapeutics, with the aim of improving extrahepatic delivery by transiently occupying liver pathways responsible for therapeutic clearance. - How does Nanobiotix describe its intellectual property?
Nanobiotix states that it owns more than 25 patent families or umbrella patents associated with three nanotechnology platforms. These patents cover applications in oncology, bioavailability and biodistribution, and central nervous system disorders. - What collaborations has Nanobiotix announced?
The company has reported a broad clinical research collaboration with The University of Texas MD Anderson Cancer Center for Phase 1 and Phase 2 studies of JNJ-1900 (NBTXR3), and a license agreement with Janssen Pharmaceutica NV for global co-development and commercialization of JNJ-1900 (NBTXR3). It has also indicated that there are numerous material transfer agreements in place for evaluations of the Curadigm Nanoprimer platform. - Is Nanobiotix included in any equity indices?
Nanobiotix has announced that it was admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, which are benchmarks for mid-sized and other listed companies in France. - What sector and industry does Nanobiotix belong to?
Based on industry classification information provided, Nanobiotix operates in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector, and it describes itself as a biotechnology company focused on nanotherapeutics and physics-based medicine.